277313-23-2

Upstream product

• 3970-21-6 2-Methoxyethoxymethyl chloride 
• 277313-22-1 methyl (3-bromo-5-formyl-4-hydroxyphenyl)acetate 
• 14199-15-6 Methyl 4-hydroxyphenylacetate 
• 1576243-71-4 sodium salt of [4-hydroxy-3-(hydroxysulfomethyl)phenyl]acetic acid methyl ester 
• 61874-04-2 (3-formyl-4-hydroxyphenyl)acetic acid methyl ester 

Downstream Products

• 871266-65-8 methyl [5'-N-tert-butylsulfamoyl-5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6-hydroxy-2'-methoxybiphenyl-3-yl]acetate 
• 871266-67-0 dibenzyl (S)-2-{2-[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6,2'-dihydroxy-5'-sulfamoylbiphenyl-3-yl]acetylamino}succinate 
• 871266-66-9 methyl [5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6-hydroxy-2′-methoxy-5′-sulfamoylbiphenyl-3-yl]acetate 
• 381210-42-0 [5-(5-cyano-1-methanesulfonyl-1H-indol-2-yl)-6-(2-methoxy-ethoxymethoxy)-3'-nitro-biphenyl-3-yl]-acetic acid methyl ester 

Relevant academic research and scientific papers

FACTOR VIIA INHIBITOR

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.

(Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors

The present invention provides novel compounds of the Formula (I): A-B, its prodrug forms, or pharmaceutically acceptable salts thereof, wherein A represents a saturated, unsaturated, or a partially unsaturated bicyclic heterocyclic ring structure, and B represents an aryl or a heteroaryl group. Preferred compounds of the present invention comprise a benzimidazole or indole nucleus. The compounds of this invention are inhibitors of serine proteases, Urokinase (uPA), Factor Xa (FXa), and/or Factor VIIa (FVIIa), and have utility as anti cancer agents and/or as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals.

FACTOR VIIA INHIBITOR

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders

2-'5-(5-CARBAMIMIDOYL-1H-HETEROARYL)-6-HYDROXYBIPHENYL-3-YL!- CARBOXYLIC ACID DERIVATIVES AS FACTOR VIIA INHIBITORS

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders. Processes for preparing these inhibitors are also disclosed.

2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.

Optimization of a screening lead for factor VIIa/TF

The structure-based design and progression of a screening lead to a 3 nM factor VIIa/TF inhibitor with improved selectivity versus related enzymes is described.